Aura Wellness PEMF

PEMF AND INFLAMATORY BOWEL DISEASE

Disclaimer: Please note that these pages are for general information purposes only. The opinions and information have not been evaluated by the FDA.  They should not be considered complete in terms of the physical conditions discussed, or construed as healthcare advice.

Parkinson’s disease (PD) is a brain disorder affecting predominately the nerve cells in a specific area of the brain called the substantia nigra leading to damage to the basal ganglia.  The basal ganglia controls much of the muscle movement of the body.  Many of the symptoms of PD are due to the breakdown or death of neurons that produce a chemical messenger in the brain called dopamine. When dopamine levels decrease, it causes abnormal brain activity, leading to impaired movement and other symptoms of PD.  Clumps of breakdown substances inside damaged brain cells are the microscopic markers of PD and are known as Lewy bodies.  Inside the Lewy Bodies, is a protein, alpha-synuclein, which cannot be broken down and eliminated.  PD is characterized by motor and non-motor symptoms. The main motor symptoms include bradykinesia (slow movement), tremor at rest (tremor affecting the body part that is relaxed or supported against gravity and not involved in purposeful activities [1]), rigidity and postural instability [2, 3, 4, 5, 6, 7]. However, motor symptoms are now considered only the “tip of the iceberg” of PD clinical manifestations.  PD non-motor symptoms include cognitive decline, decrease in sleep efficiency, increased wake after sleep onset, sleep fragmentation, and vivid dreams as well as neuropsychiatric symptoms such as depression and psychosis, [8, 9, 10, 11, 12,13].  Pain syndromes and autonomic dysfunctions have also been observed in PD patients [14, 15, 16].  Individuals with PD are often impacted by their non-motor symptoms as much or more than motor symptoms.  While Parkinson’s itself is not fatal, disease complications can be serious.  Although there is no cure, treatment options vary and include medications, surgery and adjuncts for activities of daily living.

In vitro (cell-line studies) and in vivo (animal studies) treatment with pulsed electromagnetic fields (PEMF) has demonstrated potential neuroprotective effects.  For example, PEMF was shown to regulate neutrophic factors such as brain derived neurotrophic factor, S100 and nerve growth factor.  These three factors help create brain cells, regulate their function and stimulate the cells ability to adapt and grow [17,18].  PEMF enhances cell proliferation (growth) and differentiation [17,19], enhances neurite growth [20], reduces apoptosis (cell death) [19], stimulates angiogenesis (blood vessel growth) [21], increases microvascular perfusion and tissue oxygenation [22], and stimulates neurogenesis (nerve cell growth) in the hippocampal dentate gyrus [23] and in the sub ventricular zone after injury to the substantia nigra [24].  The molecular mechanisms of PEMF are not yet fully understood.  However, PEMF may affect the tissue directly by the interactions between the electromagnetic fields (EMF) and conductive tissue, and indirectly by initiating biological events leading to a physiologic response [25].

PEMF stimulation of the ventral intermediate nucleus of the thalamus can dramatically relieve PD associated tremor [26,27].  Similarly, stimulation of the Subthalamic nucleus or globus pallidus interna (GPi) can substantially reduce rigidity, tremor, gait difficulties, and slowness in movement in patients [26, 28, 29, 30, 31].  Moreover, PEMF therapy improved PD associated freezing (a symptom manifesting as a sudden attack of immobility usually experienced during walking [32]).  Stimulation of the GPi also reduces all of the major PD motor manifestations, including the reduction of l-dopa-induced dyskinesias (medication induced muscle dysfunction) and involuntary movements produced by individual doses of dopaminergic medications that can limit treatment efficacy [33].  PD patients treated with PEMF saw significant improvement in motor symptoms, tremor, rigidity and akinesia (loss of voluntary movement), which allowed the patient to decrease the amount of the medication l-dopa they were taking by a mean of 55% [34].

PEMF increases the release of dopamine in the striatum and frontal cortex, which in turn improves PD symptoms including motor performance [35].  Furthermore, PEMF applied in the prefrontal cortex induces the release of endogenous (made by the body) dopamine in the ipsilateral caudate nucleus as observed by positron emission tomography (PET imaging) in healthy human subjects [36].  PEMF application results in partial or complete disappearance of muscular pain and l-dopa-induced dyskinesia as well as the improvement of visuospatial (ability to see the space relationship of objects) impairment, suggesting that PEMF has a beneficial effect on corticostriatal (the pathway of information flow into the basal ganglia) interactions that play an important role in the pathophysiology (development and progression) of PD [37,38].

In 2008, the Food and Drug Administration approved the use of PEMF for major depressive disorder in PD patients who failed to achieve satisfactory improvement from very high dosages of antidepressant medications [39,40].  Several studies reported PEMF improved cognitive functions and motor symptoms. For example, an investigation involving three elderly PD patients with cognitive impairment assessed the effect of PEMF on macrosomatognosia, a disorder of body image in which the patient perceives a part or parts of his body as disproportionately large [41].  PEMF applied to the frontal cortex can effectively alleviate PD associated depression as shown by a significant decrease in the Hamilton Depression Rating Scale (HDRS) scores [42].  A further double blind, sham stimulation-controlled, randomized study, involving 42 PD patients affected by major or minor depression undergoing PEMF, evidenced a mean decrease in HDRS and Beck depression inventory after therapy [43].

PD affects the right prefrontal area, causing executive dysfunction which is characterized by deficits in internal control of attention, set shifting, planning, inhibitory control, dual task performance, decision-making and social cognition tasks [44,45].  PEMF sessions were found to enhance not only executive function, but subjective symptoms and objective findings of higher cognition, planning, personality, and proper social behavior [44,46].

Pulsed Electromagnetic fields (PEMF) opens a new avenue for PD treatment and can be tailored to the PD patient’s needs.  Furthermore, PEMF can also be combined with pharmacological or non-pharmacological treatments, e.g., physical therapy and cognitive tasks, to produce additive or potentiated clinical effects. 

In conclusion, pulsed electromagnetic fields represents a non-invasive, safe and promising approach that can be used alone or combined with conventional therapies for the challenging treatment of PD motor and non-motor symptoms.

Dr. Amanda Myers, MD, MSPH

Aura Medical Director

1 Chou KL. Diagnosis and management of the patient with tremor. Med Health R I. 2004;87(5):135–138.

2 Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39(6):889–909. doi: 10.1016/S0896-6273(03)00568-3.

3 McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord. 2004;10(1):S3–S7. doi: 10.1016/j.parkreldis.2004.01.005.

4 Mendez I, Viñuela A, Astradsson A, Mukhida K, Hallett P, Robertson H, et al. Dopamine neurons implanted into people with Parkinson’s disease survive without pathology for 14 years. Nat Med. 2008;14(5):507–509. doi: 10.1038/nm1752.

5 Richardson PJ, Kase H, Jenner PG. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson’s disease. Trends Pharmacol Sci. 1997;18(9):338–344. doi: 10.1016/S0165-6147(97)01096-1.

6 Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, et al. Novel pharmacological targets for the treatment of Parkinson’s disease. Nat Rev Drug Discov. 2006;5(10):845–854. doi: 10.1038/nrd2087.

7 Bezard E, Gerlach I, Moratalla R, Gross CE, Jork R. 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson’s disease. Neurobiol Dis. 2006;23(1):77–86. doi: 10.1016/j.nbd.2006.02.003.

8 Poryazova RG, Zachariev ZI. REM sleep behavior disorder in patients with Parkinson’s disease. Folia Med (Plovdiv) 2005;47(1):5–10.

9 Eisensehr I, v Lindeiner H, Jäger M, Noachtar S. REM sleep behavior disorder in sleep-disordered patients with versus without Parkinson’s disease: is there a need for polysomnography? J Neurol Sci. 2001;186(1–2):7–11. doi: 10.1016/S0022-510X(01)00480-4.

10 Kales A, Ansel RD, Markham CH, Scharf MB, Tan TL. Sleep in patients with Parkinson’s disease and normal subjects prior to and following levodopa administration. Clin Pharmacol Ther. 1971;12(2):397–406.

11 Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson’s disease. Mov Disord Off J Mov Disord Soc. 1990;5(4):280–285. doi: 10.1002/mds.870050404.

12 Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson’s disease. Clin Neuropharmacol. 1988;11(6):512–519. doi: 10.1097/00002826-198812000-00004.

13 Comella CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson’s disease. Neurology. 1998;51(2):526–529. doi: 10.1212/WNL.51.2.526.

14 Chaudhuri KR, Healy DG, Schapira AH, FmedSci Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–245. doi: 10.1016/S1474-4422(06)70373-8.

15 Lieberman A. Depression in Parkinson’s disease—a review. Acta Neurol Scand. 2006;113(1):1–8. doi: 10.1111/j.1600-0404.2006.00536.x.

16 Poewe W. Non-motor symptoms in Parkinson’s disease. Eur J Neurol. 2008;15(1):14–20. doi: 10.1111/j.1468-1331.2008.02056.x.

17 Hei WH, Byun SH, Kim JS, Kim S, Seo YK, Park JC, et al. Effects of electromagnetic field (PEMF) exposure at different frequency and duration on the peripheral nerve regeneration: in vitro and in vivo study. Int J Neurosci. 2016;126(8):739–48. 10.3109/00207454.2015.1054032.

18 Longo FM, Yang T, Hamilton S, Hyde JF, Walker J, Jennes L, et al. Electromagnetic fields influence NGF activity and levels following sciatic nerve transection. JNeurosciRes. 1999;55(2):230–7. 10.1002/(SICI)1097-4547(19990115)55:2<230::AID-JNR10>3.0.CO;2-3.

19 Urnukhsaikhan E, Cho H, Mishig-Ochir T, Seo YK, Park JK. Pulsed electromagnetic fields promote survival and neuronal differentiation of human BM-MSCs. Life Sci. 2016;151:130–8. 10.1016/j.lfs.2016.02.066.

20 Zhang Y, Ding J, Duan W. A study of the effects of flux density and frequency of pulsed electromagnetic field on neurite outgrowth in PC12 cells. J Biol Phys. 2006;32(1):1–9. 10.1007/s10867-006-6901-2.

21 Tepper OM, Callaghan MJ, Chang EI, Galiano RD, Bhatt KA, Baharestani S, et al. Electromagnetic fields increase in vitro and in vivo angiogenesis through endothelial release of FGF-2. FASEB J. 2004;18(11):1231–3. 10.1096/fj.03-0847fje.

22 Bragin DE, Statom GL, Hagberg S, Nemoto EM. Increases in microvascular perfusion and tissue oxygenation via pulsed electromagnetic fields in the healthy rat brain. J Neurosurg. 2015;122(5):1239–47. 10.3171/2014.8.JNS132083.

23 Cuccurazzu B, Leone L, Podda MV, Piacentini R, Riccardi E, Ripoli C, et al. Exposure to extremely low-frequency (50 Hz) electromagnetic fields enhances adult hippocampal neurogenesis in C57BL/6 mice. Exp Neurol. 2010;226(1):173–82. 10.1016/j.expneurol.2010.08.022. 

24 Arias-Carrion O, Verdugo-Diaz L, Feria-Velasco A, Millan-Aldaco D, Gutierrez AA, Hernandez-Cruz A, et al. Neurogenesis in the subventricular zone following transcranial magnetic field stimulation and nigrostriatal lesions. Journal of neuroscience research. 2004;78(1):16–28. 10.1002/jnr.20235.

25 Di Lazzaro V, Capone F, Apollonio F, Borea PA, Cadossi R, Fassina L, et al. A consensus panel review of central nervous system effects of the exposure to low-intensity extremely low-frequency magnetic fields. Brain Stimul. 2013;6(4):469–76. 10.1016/j.brs.2013.01.004.

26 Dipti P, Yogesh B, Kain AK, Pauline T, Anju B, Sairam M, et al. Lead induced oxidative stress: beneficial effects of Kombucha tea. Biomed Environ Sci. 2003;16(3):276–282.

27 Benabid AL, Pollak P, Gao D, Hofmann D, Limousin P, Gay E, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg. 1996;84(2):203–214. doi: 10.3171/jns.1996.84.2.0203.

28 Elahi B, Chen R. Effect of transcranial magnetic stimulation on Parkinson motor function—systematic review of controlled clinical trials. Mov Disord. 2009;24(3):357–363. doi: 10.1002/mds.22364.

29 Zhao XD, Cao YQ, Liu HH, Li FQ, You BM, Zhou XP. Long term high frequency stimulation of STN increases dopamine in the corpus striatum of hemiparkinsonian rhesus monkey. Brain Res. 2009;1286:230–238. doi: 10.1016/j.brainres.2009.06.069.

30 Anderson VC, Burchiel KJ, Hogarth P, Favre J, Hammerstad JP. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol. 2005;62(4):554–560. doi: 10.1001/archneur.62.4.554.

31 Poulet E, Haesebaert F, Saoud M, Suaud-Chagny MF, Brunelin J. Treatment of schizophrenic patients and rTMS. Psychiatr Danub. 2010;22(1):S143–S146.

32 Sandyk R. Freezing of gait in Parkinson’s disease is improved by treatment with weak electromagnetic fields. Int J Neurosci. 1996;85(1–2):111–124. doi: 10.3109/00207459608986356.

33 Peppe A, Pierantozzi M, Altibrandi MG, Giacomini P, Stefani A, Bassi A, et al. Bilateral GPi DBS is useful to reduce abnormal involuntary movements in advanced Parkinson’s disease patients, but its action is related to modality and site of stimulation. Eur J Neurol Off J Eur Fed Neurol Soc. 2001;8(6):579–586.

34 Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med. 2003;349(20):1925–1934. doi: 10.1056/NEJMoa035275.

35 Ben-Shachar D, Belmaker RH, Grisaru N, Klein E. TMS induces alterations in brain monoamines. J Neural Trans. 1997;104:191–197. doi: 10.1007/BF01273180.

36 Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci. 2001;21(15):RC157.

37 Sandyk R. Reversal of visuospatial deficit on the Clock Drawing Test in Parkinson’s disease by treatment with weak electromagnetic fields. Int J Neurosci. 1995;82(3–4):255–268. doi: 10.3109/00207459508999805.

38 Anninos P, Adamopoulos A, Kotini A, Tsagas N, Tamiolakis D, Prassopoulos P. MEG evaluation of Parkinson’s diseased patients after external magnetic stimulation. Acta Neurol Belg. 2007;107(1):5–10.

39 Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull. 2009;42(2):5–38.

40 Liboff AR (2004) Signal shapes in electromagnetic therapies: a primer. In: Rosch PJ, Markov MS (eds) Bioelectromagnetic medicine. Marcel Dekker, NY, pp 17–37.

41 Sandyk R. Reversal of a body image disorder (macrosomatognosia) in Parkinson’s disease by treatment with AC pulsed electromagnetic fields. Int J Neurosci. 1998;93(1–2):43–54. doi: 10.3109/00207459808986411.

42 Dragasevic N, Potrebic A, Damjanović A, Stefanova E, Kostić VS. Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson’s disease: an open study. Mov Disord Off J Mov Disord Soc. 2002;17(3):528–532. doi: 10.1002/mds.10109.

43 Fregni F, Santos CM, Myczkowski ML, Rigolino R, Gallucci-Neto J, Barbosa ER, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75(8):1171–1174. doi: 10.1136/jnnp.2003.027060.

44 Furukawa T, Izumi S, Toyokura M, Masakado Y. Effects of low-frequency repetitive transcranial magnetic stimulation in Parkinson’s disease. Tokai J Exp Clin Med. 2009;34(3):63–71.

45 Dirnberger G, Jahanshahi M. Executive dysfunction in Parkinson’s disease: a review. J Neuropsychol. 2013;7(2):193–224. doi: 10.1111/jnp.12028.

46 Narayanan NS, Rodnitzky RL, Uc EY. Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease. Rev Neurosci. 2013;24(3):267–278. doi: 10.1515/revneuro-2013-0004.